Kazia Therapeutics Limited American Depositary Shares

Over 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs fr...

Kazia Therapeutics Limited (NASDAQ: KZIA) announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Levine brings over two decades of experience in investment banking and biotech financial leadership, including previous CFO roles at Cardiff Oncology and Cidara Therapeutics, where he led major pharmaceutical par...

The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and ot...

Kazia Therapeutics announced the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The lead candidate MSETC is designed to restore immune signaling in tumors resistant to immunotherapy. Kazia plans to advance the SETDB1 program alongside its PD-L1 degrader platform to IND readiness within 1...

Kazia Therapeutics announced that its CEO will participate in the J.P. Morgan Healthcare Conference week in San Francisco. The company expects to provide a clinical and translational update before month-end from its Phase 1b trial evaluating paxalisib in advanced triple-negative breast cancer, including additional clinical response observations a...